News

NIH and Partners to Launch HIV Vaccine Efficacy Trial in the Americas and Europe

August 27, 2019

The National Institutes of Health and partners today announced plans to conduct a Phase 3 HIV vaccine efficacy trial at multiple clinical research sites in North America, South America and Europe. The trial, called HPX3002/HVTN 706 or Mosaico, will assess whether an investigational vaccine regimen designed to induce immune responses against a variety of global HIV strains can safely and effectively prevent HIV acquisition among men who have sex with men and transgender people.

Improving Outcomes for Sepsis Patients

August 2, 2019

More than 1 million sepsis survivors are discharged annually from acute-care hospitals in the United States. Although the majority of these patients receive post-acute care (PAC) services, with more than one-third coming to home health care (HHC), sepsis survivors account for a majority of readmissions nationwide. Effective interventions are needed to decrease these poor outcomes.

Scientists Pinpoint New Mechanism That Impacts HIV Infection

July 24, 2019

A team of scientists led by Texas Biomed's Assistant Professor Smita Kulkarni, PhD and Mary Carrington, PhD, at the Frederick National Laboratory for Cancer Research, published results of a study that pinpointed a long noncoding RNA molecule which influences a key receptor involved in HIV infection and progression of the disease.

Genes Linked to Sepsis-Related Death are Identified in Mouse Model

July 23, 2019

Sepsis is a life-threatening condition that occurs when the body’s immune response to infection spirals out of control. Bacteria in the bloodstream trigger immune cells to release powerful molecules called cytokines to quickly activate the body’s defenses.

Pages